Management of Anticoagulation and Amiodarone During Cardioversion in NPO Patients
Eliquis (apixaban) should be continued without interruption during cardioversion even when the patient is NPO, while the amiodarone drip should also be maintained throughout the procedure to reduce the risk of thromboembolism and maintain rhythm control.
Anticoagulation Management During Cardioversion
Eliquis (Apixaban) Management
- Direct oral anticoagulants (DOACs) like apixaban are recommended in preference to vitamin K antagonists in eligible patients undergoing cardioversion 1
- Continuous anticoagulation is critical during the peri-cardioversion period to prevent thromboembolism
- For patients who are NPO:
- Apixaban should NOT be held during the NPO period
- The risk of thromboembolism outweighs concerns about missed doses
- Recent Finnish registry data shows that most post-cardioversion strokes are associated with not using anticoagulation 2
Rationale for Continuing Apixaban
- The highest risk of stroke and thromboembolism is in the first 72 hours after cardioversion 2
- Even brief interruptions in anticoagulation during this critical period can significantly increase thromboembolic risk
- Studies show that DOACs are effective and safe for patients undergoing cardioversion, with low incidence (approximately 1%) of adverse outcomes 3
Amiodarone Management During Cardioversion
Amiodarone Drip Management
- The amiodarone drip should be continued during the NPO period and cardioversion procedure
- Intravenous amiodarone is specifically recommended for cardioversion in patients with:
- Severe left ventricular hypertrophy
- Heart failure with reduced ejection fraction (HFrEF)
- Coronary artery disease 1
- Amiodarone is relatively safe in patients with structural heart disease and depressed left ventricular function 4
Rationale for Continuing Amiodarone
- Amiodarone helps maintain rhythm control during and after cardioversion
- Discontinuing the amiodarone infusion may increase the risk of immediate post-cardioversion arrhythmia recurrence
- The drug has a long half-life, but maintaining therapeutic levels during the procedure is important for successful cardioversion and maintenance of sinus rhythm
Post-Cardioversion Management
- Anticoagulation should be continued for at least 4 weeks after cardioversion in all patients 1
- Long-term anticoagulation should be maintained in patients with thromboembolic risk factors regardless of whether sinus rhythm is achieved 1
- The decision about long-term anticoagulation therapy should be based on the thromboembolic risk profile and bleeding risk profile 5
Important Considerations and Pitfalls
- Common Pitfall: Unnecessarily holding anticoagulation during NPO periods increases thromboembolic risk
- Caution: Ensure adequate IV access for amiodarone administration throughout the procedure
- Monitoring: Close hemodynamic monitoring is essential during amiodarone infusion, particularly in patients with heart failure or hypotension
- Post-procedure: Resume oral medications as soon as the patient can safely swallow to maintain therapeutic levels
Remember that atrial mechanical dysfunction can persist for several weeks following cardioversion even if sinus rhythm is restored on ECG 2, making continuous anticoagulation critical during this period.